Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roquefort Investments PLC ( (GB:ROQ) ) just unveiled an announcement.
Roquefort Therapeutics announced its interim results for the first half of 2025, highlighting a strategic pivot towards clinical stage assets. The company has signed agreements to sell its subsidiaries, Lyramid and Oncogeni, to focus on acquiring Coiled Therapeutics, a clinical stage oncology company. This acquisition aims to advance the AO-252 therapy, which is in Phase I trials for various cancers. The company also plans to progress its STAT-6 program into clinical trials, indicating a significant shift in its operational focus and potential value creation for stakeholders.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, focusing on developing clinical stage assets. The company is transitioning from pre-clinical assets to more mature clinical stage assets, with a market focus on oncology therapies.
Average Trading Volume: 1,899,630
Technical Sentiment Signal: Hold
Current Market Cap: £3.39M
For a thorough assessment of ROQ stock, go to TipRanks’ Stock Analysis page.